Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Several Blockbuster Biopharmaceuticals Going Off-patent over the Next Five to Ten Years
4.2.2 Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness
4.3 Market Restraints
4.3.1 Concerns Regarding Substitutability and Interchangeability
4.3.2 Regulatory Uncertainty
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Diagnostics
5.1.1.1 Single Photon Emission Computed Tomography (SPECT)
5.1.1.2 Positron Emission Tomography (PET)
5.1.2 By Therapeutics
5.1.2.1 Alpha Emitters
5.1.2.2 Beta Emitters
5.1.2.3 Brachytherapy
5.2 By Application
5.2.1 Cardiology
5.2.2 Neurology
5.2.3 Oncology
5.2.4 Other Applications
5.3 Geography
5.3.1 Asia-Pacific
5.3.1.1 China
5.3.1.2 Japan
5.3.1.3 India
5.3.1.4 Australia
5.3.1.5 South Korea
5.3.1.6 Rest of Asia-Pacific


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Lantheus Medical Imaging, Inc.
6.1.3 Bracco Imaging SpA
6.1.4 Nordion, Inc.
6.1.5 IBA Molecular Imaging
6.1.6 Siemens Healthcare
6.1.7 Cardinal Health, Inc.
6.1.8 NTP Radioisotopes


7 MARKET OPPORTUNITIES AND FUTURE TRENDS